Video file Sorry, your browser doesn't support embedded videos THE LATEST News & Media Stay updated on Carlyle’s latest news and insights from around the world. Carlyle in the News CNBC Companies DEI plans often stall at ‘frozen middle management—here’s how to fix it WSJ CARLYLE’S TRADITIONAL ENERGY STRATEGY GOES BEYOND DIVESTING Fortune Private equity giant Carlyle thinks its found the formula for incentivizing diversity work WSJ CARLYLE’S RUULKE BAGIJN SAYS MARKET VOLATILITY CREATES SECONDARY OPPORTUNITIES Spotify Investing with Carlyle's Sandra Horbach Reuters Carlyle backs solar developer Aspen Power with $350 mln investment
03 February 2023 Carlyle and Stellex Reach Definitive Agreement to Sell Titan to an Affiliate of Lone Star Funds
01 February 2023 Carlyle serves as Administrative Agent, Joint Lead Arranger and Bookrunner on the Senior Debt Financing of Apex Companies
26 January 2023 AlphaStruxure to Design, Construct, and Operate JFK’s New Terminal One Microgrid, Creating the Largest Rooftop Terminal Solar Array in the U.S.
19 January 2023 Carlyle to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Investor Conference Call
18 January 2023 Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies
03 February 2023 Carlyle and Stellex Reach Definitive Agreement to Sell Titan to an Affiliate of Lone Star Funds
01 February 2023 Carlyle serves as Administrative Agent, Joint Lead Arranger and Bookrunner on the Senior Debt Financing of Apex Companies
26 January 2023 AlphaStruxure to Design, Construct, and Operate JFK’s New Terminal One Microgrid, Creating the Largest Rooftop Terminal Solar Array in the U.S.
19 January 2023 Carlyle to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Investor Conference Call
18 January 2023 Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies